Clinical trials · Pennsylvania
Advanced or Metastatic Solid Tumors clinical trials in Pennsylvania
We’re tracking 378 recruiting advanced or metastatic solid tumors studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Philadelphia, PennsylvaniaAges 1 month–17 years - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Allentown, PennsylvaniaAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Bethlehem, PennsylvaniaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Bethlehem, PennsylvaniaAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Pittsburgh, PennsylvaniaAges 18–90 - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Hershey, PennsylvaniaAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Wynnewood, PennsylvaniaAges 18 years+ - NCT06644781RecruitingPhase 3
Study of Ifinatamab Deruxtecan for advanced esophageal cancer
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
Hershey, PennsylvaniaAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
York, PennsylvaniaAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06600321RecruitingPhase 1
Study of ALN-BCAT for liver cancer
This trial tests a new drug called ALN-BCAT for people with advanced liver cancer (hepatocellular carcinoma) that has a specific genetic change. If you have already tried at least one treatment, this study may be an option for you.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests an experimental pill called zongertinib for people with different types of advanced solid tumors that have a specific genetic change called HER2. It's a treatment option when other therapies haven't worked, and it may help shrink or slow the cancer.
Wynnewood, PennsylvaniaAges 18 years+ - NCT06481592RecruitingPhase 2
Study of lifileucel for advanced endometrial cancer
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Pittsburgh, PennsylvaniaAges 18–70 - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Easton, PennsylvaniaAges 18 years+ - NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05727904RecruitingPhase 3
New immunotherapy for advanced melanoma, with or without lifileucel
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Easton, PennsylvaniaAges 18–70 - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05646862RecruitingPhase 3
Comparing two treatments for advanced breast cancer with a PIK3CA mutation
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Bryn Mawr, PennsylvaniaAges 18 years+ - NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Philadelphia, PennsylvaniaAges 18–90 - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Philadelphia, PennsylvaniaAges 8 years+
Advanced or Metastatic Solid Tumors trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Research Site · 3 studies
- St. Luke's University Health Network · 3 studies
- UPMC Hillman Cancer Center · 3 studies
- Fox Chase Cancer Center · 2 studies
- Thomas Jefferson University · 2 studies
- Abramson Cancer Center Chester County Hospital
- Abramson Cancer Center of The University of Pennsylvania
- Allegheny General Hospital
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in Pennsylvania?
- Yes. We're currently tracking 378 recruiting advanced or metastatic solid tumors studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.